Unknown

Dataset Information

0

Preclinical Validation of a Single-Treatment Infusion Modality That Can Eradicate Extremity Melanomas.


ABSTRACT: Isolated limb perfusion (ILP) with the chemotherapeutic agent melphalan is an effective treatment option for extremity in-transit melanoma but is toxic and technically challenging to deliver locoregionally. CBL0137 is an experimental clinical drug with broad anticancer activity in animal models, owing to its ability to bind DNA in a nongenotoxic manner and inactivate the FACT chromatin modulator essential for tumor cell viability. Here, we report that CBL0137 delivered by ILP in a murine melanoma model is as efficacious as melphalan, displaying antitumor activity at doses corresponding to only a fraction of the systemic MTD of CBL0137. The ability to bind DNA quickly combined with a favorable safety profile made it possible to substitute CBL0137 in the ILP protocol, using an intra-arterial infusion method, to safely achieve effective tumor suppression. Our findings of a preclinical proof of concept for CBL0137 and its administration via intra-arterial infusion as a superior treatment compared with melphalan ILP allows for locoregional treatment anywhere a catheter can be placed. Cancer Res; 76(22); 6620-30. ©2016 AACR.

SUBMITTER: Kim M 

PROVIDER: S-EPMC5609527 | BioStudies | 2016-01-01

REPOSITORIES: biostudies

Similar Datasets

2018-01-01 | S-EPMC6286961 | BioStudies
2020-01-01 | S-EPMC6959433 | BioStudies
1000-01-01 | S-EPMC3764318 | BioStudies
1000-01-01 | S-EPMC4170497 | BioStudies
1000-01-01 | S-EPMC4769719 | BioStudies
2010-02-26 | GSE19293 | GEO
2010-03-09 | E-GEOD-19293 | ArrayExpress
2011-12-22 | E-GEOD-34599 | ArrayExpress
2011-01-01 | GSE22968 | GEO
2018-01-01 | S-EPMC6292929 | BioStudies